Svedbom, Axel http://orcid.org/0000-0003-2596-1679
Borgstöm, Fredrik
Hernlund, Emma
Alekna, Vidmantas
Bianchi, Maria Luisa
Clark, Patricia
Diaz-Curiel, Manuel
Dimai, Hans Peter
Jürisson, Mikk
Lesnyak, Olga
McCloskey, Eugene
Sanders, Kerrie M.
Silverman, Stuart
Tamulaitiene, Marija
Thomas, Thierry
Tosteson, Anna N. A.
Jönsson, Bengt
Kanis, John A.
Funding for this research was provided by:
Amgen
Eli Lilly and Company
Medtronic
Novartis
Sanofi
Servier
Pfizer
Merck Pty Ltd
the National Health and Medical Research Council (628422)
Hauptverband der österreichischen Soziaversicherungs-träger
Austrian Society for Bone and Mineral Research
Merck Sharp and Dohme
Servier GmbH
Medtronic GmbH
Amgen GmbH
Novartis GmbH
Nycomed GmbH
Roche GmbH
Sanofi-Aventis GmbH
Daiichi-Sankyo GmbH
CONACyT (El 2008-01-87106)
Lithuania National Osteoporosis Center
Ingenix Pharmaceutical Services
Medtronic Spine LLC
Estonian Science Foundation (9368)
Estonian Ministry of Education and Research (IUT 34-17, IUT 2-)
Russian Osteoporosis Association
Karolinska Institute
Article History
Accepted: 12 November 2022
First Online: 10 December 2022
Declarations
:
: During development of the manuscript, a contract research organization. FB is employed by and own equity in Quantify Research, a contract research organization. JAK received consultancies/speaking fees from AgNovos healthcare, Amgen, D3A, Lilly, Medimaps, Unigene, Radius Health, Pfizer, Servier, and Takeda; and research support from Asahi, Amgen, GSK, Lilly, Medtronic, Novartis, Pfizer, Sanofi-Aventis, Servier, and Warner Chilcott. EM received consultancies, honoraria and speaking fees from Active Signal, Alliance for Better Bone Health, Amgen, Bayer, Boehringer Ingelheim, Consilient Healthcare, Eli Lilly, GE Lunar, GSK, Hologic, Internis, Medtronic, Merck, Novartis, Pfizer, Roche, Servier, Synexus, Tethys, and UCB; and research funding from the Alliance for Better Bone Health, Amgen, Arthritis Research UK, EPSRC, Internis, Medical Research Council, and NIHR. HPD reports consultancies, honoraria and speaking fees from Amgen, BRAINCON, Daiichi-Sankyo, Eli Lilly, Merck Sharp & Dohme, Novartis, Nycomed, Servier, Sinapharm, Alexion, Daiichi-Sankyo, Genericon, Kyphon, and Genericon. TT reports consultancies, honoraria and speaking fees, and grants from Abbvie, Amgen, BMS, Chugai/Roche, Eli Lilly, Expanscience, Gilead, Merck Sharp & Dohme, Medac, Thuasne, UCB, HAC-Pharma, LCA, Novartis, Pfizer, Servier, and TEVA. The remaining authors report no conflict of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Ethics approval were obtained for all countries with the following record identification numbers: Australia (Barwon health human ethics research committee) BH HREC 09/49; Austria (Medical University of Graz) 18-001 ex 06/07; Estonia (University of Tartu) 192/T-4; France (Commission NAtionale de l’informatique et des Libertes /Direction Generale del la Recherce et de l’innovation) AT/YPA/SV/SN/GDP/EM/AR081020; Lithuania (Lithuanian Bioethics Committee) 2007-06-21 Nr. 16; Italy (Istituto Auxologico Italiano) 02A603; Mexico (Hospital Infantil de Mexico Federico Gómez) FMED/CI/GRD/042/06/2008; Russia (Ural State Medical University) 1.14.03.2007; Spain (Institut Municipal d’Assistencia Sanitaria, Barcelona) 26/09/2007; UK (South Yorkshire Research Ethics Committee): 09/H1310/53.
: Informed consent was obtained from all individual participants included in the study and all study participants could with draw from the study at any time at their own request.